{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:41Z","timestamp":1791919601925,"version":"4.3.4"},"reference-count":148,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The mTOR pathway plays a central role in many cellular processes, such as cellular growth, protein synthesis, glucose, and lipid metabolism. Aberrant regulation of mTOR is a hallmark of many cancers, including hematological malignancies. mTOR inhibitors, such as Rapamycin and Rapamycin analogs (Rapalogs), have become a promising class of agents to treat malignant blood diseases\u2014either alone or in combination with other treatment regimens. This review highlights experimental evidence underlying the molecular mechanisms of mTOR inhibitors and summarizes their evolving role in the treatment of hematologic disease, including leukemia, lymphoma, myeloma, immune hemocytopenia, and graft-versus-host disease (GVHD). Based on data presented in this review, we believe that mTOR inhibitors are becoming a trusted therapeutic in the clinical hematologist\u2019s toolbelt and should be considered more routinely in combination therapy for the management of hematologic disease.<\/jats:p>","DOI":"10.3389\/fonc.2020.611690","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T14:15:16Z","timestamp":1610201716000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside"],"prefix":"10.3389","volume":"10","author":[{"given":"Yimei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaniel","family":"Cassady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-25.5.459","article-title":"A Pediatric Case of Sirolimus-Associated Pneumonitis After Kidney Transplantation","volume":"25","author":"Kelchtermans","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3022478","article-title":"Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives","volume":"3","author":"Dufour","year":"2011","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/cells8040333","article-title":"mTOR Signalling in Head and Neck Cancer: Heads Up","volume":"8","author":"Tan","year":"2019","journal-title":"Cells"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.23.648","article-title":"Intracellular signal transduction pathway proteins as targets for cancer therapy","volume":"23","author":"Adjei","year":"2005","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20102103","article-title":"Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney","volume":"436","author":"Pearce","year":"2011","journal-title":"Biochem J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.68","article-title":"Toward rapamycin analog (rapalog)-based precision cancer therapy","volume":"36","author":"Meng","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3944-09.2010","article-title":"Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease","volume":"30","author":"Malagelada","year":"2010","journal-title":"J Neurosci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01174.2006","article-title":"Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells","volume":"292","author":"Ma","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.101.4.1","article-title":"Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition","volume":"4","author":"Goudar","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/08830185.2014.933957","article-title":"mTOR Signaling in T Cell Immunity and Autoimmunity","volume":"34","author":"Liu","year":"2015","journal-title":"Int Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32833e5b2e","article-title":"Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update","volume":"17","author":"Cutler","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.170","article-title":"Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies","volume":"24","author":"Chapuis","year":"2010","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2004.40.2.799422","article-title":"Everolimus - A proliferation signal inhibitor targeting primary causes of allograft dysfunction","volume":"40","author":"Kovarik","year":"2004","journal-title":"Drugs Today"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp504","article-title":"Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel","volume":"21","author":"Sessa","year":"2010","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","article-title":"Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas","volume":"30","author":"Chawla","year":"2012","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.07.008","article-title":"Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer","volume":"15","author":"Seiler","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents","volume":"363","author":"Serruys","year":"2010","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2407-13-308","article-title":"A phase I\/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial","volume":"13","author":"Witzens-Harig","year":"2013","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318155a439","article-title":"A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)","volume":"2","author":"Pandya","year":"2007","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.10.010","article-title":"Evaluating temsirolimus activity in multiple tumors: a review of clinical trials","author":"Dancey","year":"2009","journal-title":"Semin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.bbrc.2017.01.031","article-title":"mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival","volume":"483","author":"Feng","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4468","article-title":"mTOR regulates cell survival after etoposide treatment in primary AML cells","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2436348100","article-title":"Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by Il-7-mediated signalling","volume":"100","author":"Brown","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-0929","article-title":"Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells","volume":"106","author":"Avellino","year":"2005","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2888","article-title":"A Phase I\/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"21","author":"Daver","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25333","article-title":"A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease","volume":"94","author":"Litzow","year":"2019","journal-title":"Am J Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0585-x","article-title":"Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition","volume":"36","author":"Kasner","year":"2018","journal-title":"Invest New Drugs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia","volume":"15","author":"Perl","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189514","article-title":"Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial","volume":"103","author":"Burnett","year":"2018","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0967-x","article-title":"Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation","volume":"34","author":"Robin","year":"2020","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.20","article-title":"Activation of the mTOR signaling pathway by L-leucine in 5q-syndrome and other RPS14-deficient erythroblasts","volume":"27","author":"Yip","year":"2013","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4409","article-title":"The Akt\/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation","volume":"67","author":"Follo","year":"2007","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077052","article-title":"Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome: Possible clinical application of rapamycin","volume":"44","author":"Maeda","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05360.x","article-title":"Activity of sirolimus in patients with myelodysplastic syndrome\u2013results of a pilot study","volume":"128","author":"Platzbecker","year":"2005","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14345","article-title":"Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)","volume":"175","author":"Wermke","year":"2016","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00883","article-title":"Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood"},{"key":"B47","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/or.2011.1502","article-title":"Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia","volume":"27","author":"Li","year":"2012","journal-title":"Oncol Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1820-5","article-title":"Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway","volume":"35","author":"Li","year":"2014","journal-title":"Tumour Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12032-019-1253-5","article-title":"Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia","volume":"36","author":"Alves","year":"2019","journal-title":"Med Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00321","article-title":"The Role of New Technologies in Myeloproliferative Neoplasms","volume":"9","author":"Palumbo","year":"2019","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J Cell Mol Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3835.3835","article-title":"Inhibitors of PI3K\/Akt and\/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon","volume":"118","author":"Vannucchi","year":"2011","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.07.011","article-title":"Rationale for targeting the PI3K\/Akt\/mTOR pathway in myeloproliferative neoplasms","author":"Bartalucci","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B59","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1471-2407-13-250","article-title":"Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease\u2013a combined tissue microarray, in vitro and in vivo study","volume":"13","author":"Mark","year":"2013","journal-title":"BMC Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016907","article-title":"Role of phosphatidylinositol 3\u2019-kinase\/AKT pathway in diffuse large B-cell lymphoma survival","volume":"108","author":"Uddin","year":"2006","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08123.x","article-title":"High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"149","author":"Hasselblom","year":"2010","journal-title":"Br J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7036","article-title":"Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma","volume":"7","author":"Ezell","year":"2016","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.14529","article-title":"m-TOR inhibitors and their potential role in haematological malignancies","volume":"177","author":"Calimeri","year":"2017","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood.V120.21.2740.2740","article-title":"Everolimus for Relapsed\/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study","volume":"120","author":"Johnston","year":"2012","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2017.03.008","article-title":"Everolimus as a single agent in refractory or relapsed Hodgkin\u2019s lymphoma: the Brazilian Named Patient Program Experience","volume":"39","author":"Rocha","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24671","article-title":"Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma","volume":"92","author":"Bennani","year":"2017","journal-title":"Am J Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"B75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clml.2018.06.013","article-title":"A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma","volume":"18","author":"Padrnos","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B77","doi-asserted-by":"publisher","first-page":"8508","DOI":"10.1200\/jco.2014.32.15_suppl.8508","article-title":"Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients","volume":"32","author":"Janku","year":"2014","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood.V122.21.3048.3048","article-title":"Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients","volume":"122","author":"Janku","year":"2013","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04159-3","article-title":"Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T(3) phase IB trial of the LYSA","volume":"99","author":"Tessoulin","year":"2020","journal-title":"Ann Hematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29502","article-title":"A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study","volume":"121","author":"Fenske","year":"2015","journal-title":"Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: The University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0189","article-title":"Rapamycin-induced G(1) arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin","volume":"101","author":"Decker","year":"2003","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20026","article-title":"Mammalian target of rapamycin inhibition as therapy for hematologic malignancies","volume":"100","author":"Panwalkar","year":"2004","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12458","article-title":"Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1alpha\/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase\/Akt\/mammalian target protein of rapamycin pathway in multiple myeloma cells","volume":"105","author":"Wang","year":"2014","journal-title":"Cancer Sci"},{"key":"B89","article-title":"Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines","volume":"80","author":"Adachi","year":"2016","journal-title":"Can J Vet Res"},{"key":"B90","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9662","article-title":"Curcumin-induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells","volume":"17","author":"Chen","year":"2019","journal-title":"Oncol Lett"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25003","article-title":"Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma","volume":"9","author":"Lamanuzzi","year":"2018","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8178","article-title":"Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma","volume":"15","author":"Jin","year":"2018","journal-title":"Oncol Lett"},{"key":"B94","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/jim-2018-000780","article-title":"Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT\/mTOR pathway","volume":"67","author":"Li","year":"2019","journal-title":"J Investig Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/jim-2018-000780","article-title":"Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT\/mTOR pathway","volume":"67","author":"Li","year":"2019","journal-title":"J Invest Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.116269","article-title":"Activity of everolimus (RAD001) in relapsed and\/or refractory multiple myeloma: a phase I study","volume":"100","author":"Gunther","year":"2015","journal-title":"Haematologica"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12909","article-title":"Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide","volume":"166","author":"Yee","year":"2014","journal-title":"Br J Haematol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4962","article-title":"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein","volume":"29","author":"Hofmeister","year":"2011","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70028-6","article-title":"Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1\/2, open-label, dose-escalation study","volume":"12","author":"Ghobrial","year":"2011","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"134","DOI":"10.21037\/atm.2019.03.04","article-title":"Enhancing autophagy protects platelets in immune thrombocytopenia patients","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/548085","article-title":"Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): A Single Institution\u2019s Experience","volume":"39","author":"Jasinski","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25119","article-title":"Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil","volume":"93","author":"Miano","year":"2018","journal-title":"Am J Hematol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00110","article-title":"Sirolimus as Rescue Therapy for Refractory\/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study","volume":"7","author":"Feng","year":"2020","journal-title":"Front Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/BOR.0000000000000523","article-title":"Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment","volume":"30","author":"Neely","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.tmrv.2015.09.001","article-title":"Sirolimus for Refractory Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review of the Treatment of Post-Transplant Autoimmune Hemolytic Anemia","volume":"30","author":"Park","year":"2016","journal-title":"Transfus Med Rev"},{"key":"B108","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000438731","article-title":"Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review","volume":"42","author":"Salama","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4692","article-title":"CD4(+) CD25(+) regulatory T cells control induction of autoimmune hemolytic anemia","volume":"105","author":"Mqadmi","year":"2005","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00348","article-title":"Regulatory T Cells Are Dispensable for Tolerance to RBC Antigens","volume":"7","author":"Richards","year":"2016","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.56.846","article-title":"Molecular mechanisms of autoimmune hemolytic anemia","volume":"56","author":"Kamesaki","year":"2015","journal-title":"Rinsho Ketsueki"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13866","article-title":"How I manage Evans Syndrome and AIHA cases in children","volume":"172","author":"Miano","year":"2016","journal-title":"Br J Haematol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12101","article-title":"Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor","volume":"17","author":"Acquazzino","year":"2013","journal-title":"Pediatr Transplant"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.690","article-title":"Warm antibody autoimmune hemolytic anemia","volume":"2016","author":"Kalfa","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.16016\/j.1000-5404.202005102","article-title":"Clinical efficacy of sirolimus in treatment of relapsed and refractory autoimmune hemolytic anemia in adults","volume":"42","author":"Yan","year":"2020","journal-title":"J Third Mil Med Univ"},{"key":"B116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12016-015-8466-y","article-title":"Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS)","volume":"50","author":"Li","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21307\/immunohematology-2019-004","article-title":"Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation","volume":"33","author":"Cooling","year":"2017","journal-title":"Immunohematology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2018.06.043","article-title":"Advance of Mechanisms and Clinical Applications about Rapamycin for Treating Immune Mediated Hemocytopenia","volume":"26","author":"Gu","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-685024","article-title":"Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome","volume":"128","author":"Volkl","year":"2016","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-010124","article-title":"Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)","volume":"108","author":"Teachey","year":"2006","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07991.x","article-title":"Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)","volume":"148","author":"Teachey","year":"2010","journal-title":"Br J Haematol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0175-3","article-title":"Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children","volume":"18","author":"George","year":"2016","journal-title":"Pediatr Drugs"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07595.x","article-title":"Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22151","article-title":"Rapid Regression of Lymphadenopathy upon Rapamycin Treatment in a Child With Autoimmune Lymphoproliferative Syndrome","volume":"53","author":"Dragana","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13533","article-title":"Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience","volume":"171","author":"Miano","year":"2015","journal-title":"Br J Haematol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00587","article-title":"Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment","volume":"8","author":"Medinger","year":"2018","journal-title":"Front Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/asheducation-2013.1.76","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"2013","author":"Young","year":"2013","journal-title":"Hematol-Am Soc Hematol Educ Program"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717693573","article-title":"From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag","volume":"8","author":"Gill","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1313700","article-title":"Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review","volume":"10","author":"Boddu","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.08.034","article-title":"Rapamycin ameliorates immune-mediated aplastic anemia by inhibiting the proliferation and metabolism of T cells","volume":"518","author":"Liu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2014.03.035","article-title":"Effects of rapamycin on biological characteristics of bone marrow mesenchymal stem cells from patients with aplastic anemia","volume":"22","author":"Wang","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22865","article-title":"Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine","volume":"56","author":"He","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13829","article-title":"Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study","volume":"94","author":"Scheinberg","year":"2009","journal-title":"Haematologica"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2018.04.011","article-title":"Effect of sirolimus on erythropoiesis of K562 cell line and patients with pure red cell aplasia in vitro","volume":"39","author":"Yang","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3778.3778","article-title":"Succesful treatment with Sirolimus in a refractory case of pure red cell aplasia (PRCA)","volume":"110","author":"Ovilla","year":"2007","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15245","article-title":"Sirolimus for the treatment of multi-resistant pure red cell aplasia","volume":"184","author":"Jiang","year":"2019","journal-title":"Br J Haematol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3431-5","article-title":"Successful treatment of refractory\/relapsed acquired pure red cell aplasia with sirolimus","volume":"97","author":"Long","year":"2018","journal-title":"Ann Hematol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and Other HSCT-Related Major Complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705628","article-title":"Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells","volume":"39","author":"Coenen","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning","volume":"26","author":"Armand","year":"2008","journal-title":"J Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.13931","article-title":"The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13110","article-title":"The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials","volume":"55","author":"Wang","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood.2019003125","article-title":"Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial","volume":"135","author":"Pidala","year":"2020","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.195123","article-title":"A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801","volume":"103","author":"Carpenter","year":"2018","journal-title":"Haematologica"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.09.003","article-title":"The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant\/steroid-dependent extensive cGVHD","volume":"41","author":"Zhu","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.611690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T02:42:11Z","timestamp":1670726531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.611690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":148,"alternative-id":["10.3389\/fonc.2020.611690"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.611690","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"article-number":"611690"}}